大肠癌个体化治疗【精品】.pptVIP

大肠癌个体化治疗实践与探讨;概　述;已经批准用于大肠癌治疗的药物;概　述;氟尿嘧啶相关代谢酶基因多态与大肠癌化疗疗效的关系; FdUMP: 5-氟尿嘧啶脱氧核苷5`-单磷酸盐 FdUrd: 5-氟尿嘧啶脱氧核苷 MS:蛋氨酸合酶 MTHFR: 亚甲基四氢叶酸还原酶 THF: 四氢叶酸 TK: 胸腺嘧啶脱氧核苷激酶 TP: 胸腺啶磷酸化酶 TYMS(TS): 胸苷酸合成酶;胸苷酸合成酶（TS）基因多态与5－FU疗效关系;TS基因多态种族差异;Association between genotypes and response to chemotherapy in the 80 patients ;亚甲基四氢叶酸还原酶（MTHFR）基因多态与5－FU疗效关系;Kaplan–Meier survival curves for patients in relation to (a) MTHFR C677T polymorphism (log rank=0.01, p=0.92) and (b) MTHFR A1298C polymorphism (log rank=10.67, p=0.001) ; MTHFR Gene Polymorphism and Response (79 patients );二氢嘧啶脱氢酶基因多态性;Association of DPYD Genotypes With Isolated Types of Toxicity;乳清酸磷酸核糖转移酶基因多态 ;UGT1A1多态与CPT－11化疗的副反应性关系;UGT1A1 status correlation with irinotecan-associated toxicity and treatment efficacy;Kras基因突变指导结直肠癌治疗;Association Between KRAS Status and Response to Panitumumab or Cetuximab Therapy in Patients With Colorectal Cancer;江苏省肿瘤医院内科在胃肠癌个体化治疗中的实践;Association Between genotype Status and Response to 5-FU base Chemotherapy in 173 Patients With advanced Gastric Cancer（2002－2008）;西妥昔单抗联合FOLFIR I方案治疗晚期大肠癌的临床观察;K-ras基因分析提高治疗疗效;基因型为基础的个体化治疗小结;基因型为基础的个体化治疗存在的问题;在药物遗传药理学研究中存在的混杂因素及可能的解决方法;展　望;谢　谢！;MGAupjd71(#UOJDxrmga4-%XRLGAuoid71*#UOIDxrlfa4-$XRLFzuoic71*ZUOICwrlf94-$WQLFztoic60*ZTNICwqlf93)$WQKFztnhc60ZTNHCwqke93)!WQKEytnhb60YSNHBvqke83)!VPKEysnhb5+YSMHBvpke82(!VPJEysmgb5+%YSMGBvpjd82(#VPJDxsmga5+%XRMGAupjd72(#UOJDxrmga4-%XRLGAuojd71*#UOIDxrlfa4-$XRLFzuoic71*ZUOICwrlf94-$WQLFztoic61*ZTNICwqlf93)$WQKFztnhc60ZTNHCwqke93)!WQKEytnhb60YTNHBvqke83)!VPKEysnhb50YSMHBvpke82(!VPJEysmgb5+%YSMGBvpjd82(#VPJDxsmga5+%XSMGAupjd72(#UOJDxrmga4-%XRLGAuojd71*#UOIDxrlfa4-$XRLFAuoic71*ZUOICwrlf94-$WRLFztoic61*ZTNICwqlf93)$WQKFztnic60ZTNHCwqke93)!WQKEztnhb60YTNHBvqke83)!VPKEysnhb50YSMHBvpke82(!VPJEysmhb5+%YSMGBvpjd82(#VPJDysmga5+%XSMGAupjd72(#UOJDxrmga4+%XRLGAuojd71*#UOIDxrlga4-$XRLFAuoic71*ZUOICwrlf94-$WRLFztoic61*ZTNICwqlf93-$WQKFztnic60ZTNHCwqkf93)!WQKEztnhb60YTNHBvqke83)!VQKEysnhb50YSMHBvpke82)!VPJEysmhb5+%YSMGBvpjd82(#VPJDysm